Navigation Links
MediPurpose® Announces U.S. Distribution Agreement With Pharmaplast, Egyptian Advanced Wound Care OEM
Date:6/22/2010

ALEXANDRIA, Egypt and NORCROSS, Ga., June 22 /PRNewswire/ -- MediPurpose®, a medical device innovation and medical product distribution company, today announced that it has signed an exclusive agreement to distribute advanced wound care products from Egypt-based OEM Pharmaplast.

The milestone agreement is the foundation for MediPurpose's recently launched Wound Care division. For Pharmaplast, it enables access to an expanded market for its products within the Americas while continuing to expand their worldwide presence.

"We are very pleased to announce our exclusive partnership with Pharmaplast," said MediPurpose COO and President Randy Prather, who oversees the Wound Care division. "Their quality and breadth of product line of advanced wound care products is the ideal foundation for our Wound Care division."

The new Wound Care division—and the subsequent agreement with Pharmaplast— spotlights MediPurpose's attention on new business development to expand medical product lines that complement their award-winning medical product distribution services and logistics capabilities.

"Our distribution services capability was a key advantage that MediPurpose was able to offer that cemented the relationship with our new OEM partner," said Prather. "MediPurpose's goal was to provide a quality, comprehensive advanced wound care line that would afford substantial profit opportunities for our existing and new distribution partners who service this market. Pharmaplast provided us the opportunity to meet and exceed those original goals."

"Additionally, with the launch of this new division, we are very excited about the opportunities to expand the division's product capabilities by partnering with additional wound care products manufacturers that offer complementary products in the Americas and abroad."

MediPurpose founder and CEO Patrick Yi added, "It is our responsibility to ensure that all our new medical product lines achieve the same superior product quality and customer service as our current SurgiLance® safety lancet product line. After an exhaustive evaluation, I am confident that our customers will receive the same standard of service from Pharmaplast."

About Pharmaplast

Started in 1985 by three pharmacists, Pharmaplast engages in the manufacture of advanced wound care and immobilization products.

Today, Pharmaplast is a shareholding company with five factories in Egypt that employ 700 employees. All factories are ISO 9001 certified, all products bear the CE mark and most of the products are FDA registered.

Pharmaplast believes that consistent innovation and quality assurance is the key to its survival, and thus invests to generate new products that help medical professionals to provide quality patient care with maximum cost-efficiency.

For more information about Pharmaplast, please visit http://www.pharmaplast-online.com.

About MediPurpose

Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.

Known for its innovation of the SurgiLance® Safety Lancet, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor.

MediPurpose also offers angel funding, medical product development and medical device consulting for medical device inventors and medical product companies seeking entrance or expansion into the medical device markets.

For more information about MediPurpose's medical products, medical distribution channel management services and medical device development services, please visit http://www.medipurpose.com.


'/>"/>
SOURCE MediPurpose
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market by Manufacturers, ... and analysed the potential of Global Effective Microorganisms (EM) Market ... growth factors. The report identifies and analyses the emerging trends ... market. ... and Figures, 6 Major Company Profiles, spread across 124 pages ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider ... Online(TM), which enables sleep physicians to create and edit their interpretation reports. This ... provides a familiar interface that does not require additional training to use. It ...
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... ... Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven one- ...
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
Breaking Medicine News(10 mins):